Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Parkinson's
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Parkinson's
    Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease - (N Engl J Med)
    TopAbstracts in Parkinson's 10/21/2009 - (DGNews)
    Study Conclusively Ties Gaucher Disease Gene to Parkinson's Disease - (DGNews)
    Rivastigmine Improves Executive Functioning in Parkinson's Disease Dementia: Presented at ANA - (DGDispatch)
    Response to Nortriptyline and Paroxetine Linked to Level of Neuropsychological Impairment in Patients With Parkinson's Disease: Presented at ANA - (DGDispatch)

    News archive

     Recent webcasts/CME - Parkinson's
      PreAnesthetic Assessment of the Patient for Deep Brain Stimulation
      The Management of Parkinson's Disease in the Primary Care Setting
      Initiating and Monitoring Pharmacotherapy in Patients with Parkinson's Disease
      Effective Management in Early Idiopathic Parkinson's Disease
      Case Studies in the Advancement of Parkinson's Disease

      Webcasts/CME archive

       Recent cases - Parkinson's
        Pleural Effusion and Pulmonary Hypertension in a Patient With Parkinson Disease Treated With Cabergoline
        Development of Parkinsonism Following Exposure to Aripiprazole: Two Case Reports
        Hypothermia with Osborn Waves in Parkinson's Disease
        HIV, Visceral Leishmaniasis and Parkinsonism Combined with Diabetes Mellitus and Hyperuricaemia: A Case Report
        Gliomatosis Cerebri Presenting as Rapidly Progressive Dementia and Parkinsonism in an Elderly Woman: A Case Report

        Cases archive
          




        my personal edition > parkinson's > news
        divider

          E-Mail this DGNews to a colleague

        DGNews


        Schwarz Pharma Announces Publication of Rotigotine Data in Neurology

          Transdermal Rotigotine Phase 3 Clinical Trial Results Published in Neurology Demonstrated Efficacy for Treatment of Early-Stage Parkinson's Disease.

          MONHEIM, GERMANY -- January 4, 2007 -- Schwarz Pharma announced the electronic publication of a pivotal phase III clinical trial in the journal, Neurology.

          This trial showed positive results of its once daily dopamine agonist, rotigotine, for the treatment of early-stage Parkinson's disease (PD). Rotigotine is a non-ergolinic dopamine receptor-agonist formulated as a transdermal delivery (through the skin) system.

          The study, titled "Randomized, Blind, Controlled Trial of Transdermal Rotigotine in Early Parkinson Disease," can be found on Neurology's web site at http://www.neurology.org.

          The multi-center, randomized, double-blind study was designed to evaluate the safety and effectiveness of the once-daily dopamine agonist rotigotine, supplied via a once daily transdermal patch that delivers the drug continuously, versus placebo in patients with early-stage PD. The author and lead investigator of the study, Ray L. Watts, MD, Director of Clinical Research and Chairman of Neurology, University of Alabama at Birmingham, concluded that rotigotine, when titrated to a dose of 6mg/24hr, was effective for the treatment of early-stage PD. In addition, rotigotine appeared to be well-tolerated by patients.

          "Parkinson's disease is a progressive disorder and this important study showed that rotigotine may be safe and effective, and potentially be of significant value in the treatment of early-stage PD," said Dr. Watts. "Rotigotine is a dopamine agonist that offers continuous drug delivery with a once-daily patch, which will hopefully mitigate the practical intra-day variability that accompanies the multiple dose regimens of other dopaminergic drugs."

          Study Design and Results
          This phase 3 clinical trial evaluated 302 patients with early-stage, idiopathic PD at 50 clinical study sites in the United States and Canada. Two hundred seventy-seven patients were randomized to receive placebo (n=96) or rotigotine (n=181). The rotigotine group started treatment with the 2mg/24hr (10 cm squared) patch and titrated weekly up to a maximum dose of 6mg/24hr (30 cm squared).

          The 27-week study period included a three-week titration phase, followed by a 24-week maintenance phase. There was also a four-week pre-treatment phase and a four-week safety follow-up phase. The primary efficacy measure was the change from baseline in parts II and III of the Unified Parkinson Disease Rating Scale (UPDRS) score, which assesses a patient's ability to perform everyday activities and also evaluates motor symptoms of PD.

          Compared with placebo, rotigotine significantly improved patients' symptoms in early-stage PD through six months of therapy as measured by parts II and III of the UPDRS (a decrease in UPDRS scores signifies symptom improvement). Patients in the placebo group had a mean increase in UPDRS subtotals of 1.31 ± 0.956, while the rotigotine group had a mean decrease in score of 3.98 ± 0.707 (P < 0.0001). The most commonly reported adverse events (>10 percent) that occurred in patients receiving rotigotine were application site reactions (which were generally mild to moderate in intensity), nausea, somnolence, dizziness, and headache.

          About Rotigotine
          Rotigotine is a non-ergolinic dopamine receptor-agonist formulated as a transdermal delivery system, a patch, designed for once-a-day application. Rotigotine is designed to mimic the action of dopamine, a naturally-produced neurotransmitter crucial for proper motor functioning. Rotigotine is currently under review with the U.S. Food and Drug Administration (FDA) for its efficacy and safety as treatment for early-stage PD. At this time, it is marketed in Europe as monotherapy for early-stage PD and has received a favorable review for advanced-stage PD.

          About Parkinson's Disease
          Parkinson's disease is a progressive disorder of the central nervous system. The patients -- roughly four million worldwide, including approximately 1 million people in the U.S. -- suffer primarily from a lack of dopamine, a messenger substance in the central nervous system, which is responsible for the coordination of movement. As a result of this shortage, patients are no longer able to control their movements reliably. Dopamine agonists are drugs that attempt to compensate for this lack of dopamine.


          SOURCE: Schwarz Pharma




        E-Mail this DGNews to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send